BACKGROUND: Persons with Barrett's esophagus have a substantially greater risk of esophageal adenocarcinoma than the general population. Higher serum selenium levels have been associated with a reduced risk of several cancers; however, their association with the risk of esophageal adenocarcinoma is unknown. We used a cross-sectional study to investigate the relationship between serum selenium levels and markers of neoplastic progression among persons with Barrett's esophagus. METHODS: Medical history, blood, and esophageal tissue specimens were collected from 399 members of a cohort study of Barrett's esophagus patients undergoing endoscopic surveillance. Serum selenium levels were measured by flameless atomic absorption spectrophotometry. DNA content of tissue samples was measured by flow cytometry. Loss of heterozygosity (LOH) at 9p and 17p, chromosomal regions which include the p16 and p53 tumor suppressors, respectively, was detected by automated fluorescent genotyping. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). All statistical tests were two-sided. RESULTS: Persons with serum selenium levels in the upper three quartiles (i.e., >1.5 micro M) were less likely to have high-grade dysplasia (OR = 0.5, 95% CI = 0.3 to 0.9) or aneuploidy (OR = 0.4, 95% CI = 0.2 to 0.8) than those with levels in the lowest quartile. Serum selenium levels in the upper three quartiles were associated with similar reductions in risk of 17p (p53) LOH (OR = 0.5, 95% CI = 0.2 to 0.9) and increased 4N fraction (OR = 0.6, 95% CI = 0.3 to 1.2). By contrast, serum selenium levels were not associated with 9p (p16) LOH (OR = 1.0, 95% CI = 0.5 to 1.7), a marker that appears early in neoplastic progression. CONCLUSION: Our preliminary results, from a cross-sectional analysis with biologic markers, suggest that higher serum selenium levels may be associated with a reduced risk of esophageal adenocarcinoma among persons with Barrett's esophagus. Because serum selenium was not associated with 9p (p16) LOH, we speculate that selenium may act primarily at later stages of progression toward adenocarcinoma.
BACKGROUND:Persons with Barrett's esophagus have a substantially greater risk of esophageal adenocarcinoma than the general population. Higher serum selenium levels have been associated with a reduced risk of several cancers; however, their association with the risk of esophageal adenocarcinoma is unknown. We used a cross-sectional study to investigate the relationship between serum selenium levels and markers of neoplastic progression among persons with Barrett's esophagus. METHODS: Medical history, blood, and esophageal tissue specimens were collected from 399 members of a cohort study of Barrett's esophaguspatients undergoing endoscopic surveillance. Serum selenium levels were measured by flameless atomic absorption spectrophotometry. DNA content of tissue samples was measured by flow cytometry. Loss of heterozygosity (LOH) at 9p and 17p, chromosomal regions which include the p16 and p53tumor suppressors, respectively, was detected by automated fluorescent genotyping. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). All statistical tests were two-sided. RESULTS:Persons with serum selenium levels in the upper three quartiles (i.e., >1.5 micro M) were less likely to have high-grade dysplasia (OR = 0.5, 95% CI = 0.3 to 0.9) or aneuploidy (OR = 0.4, 95% CI = 0.2 to 0.8) than those with levels in the lowest quartile. Serum selenium levels in the upper three quartiles were associated with similar reductions in risk of 17p (p53) LOH (OR = 0.5, 95% CI = 0.2 to 0.9) and increased 4N fraction (OR = 0.6, 95% CI = 0.3 to 1.2). By contrast, serum selenium levels were not associated with 9p (p16) LOH (OR = 1.0, 95% CI = 0.5 to 1.7), a marker that appears early in neoplastic progression. CONCLUSION: Our preliminary results, from a cross-sectional analysis with biologic markers, suggest that higher serum selenium levels may be associated with a reduced risk of esophageal adenocarcinoma among persons with Barrett's esophagus. Because serum selenium was not associated with 9p (p16) LOH, we speculate that selenium may act primarily at later stages of progression toward adenocarcinoma.
Authors: G E Goodman; M Thornquist; M Kestin; B Metch; G Anderson; G S Omenn Journal: Cancer Epidemiol Biomarkers Prev Date: 1996-10 Impact factor: 4.254
Authors: M T Barrett; C A Sanchez; L J Prevo; D J Wong; P C Galipeau; T G Paulson; P S Rabinovitch; B J Reid Journal: Nat Genet Date: 1999-05 Impact factor: 38.330
Authors: Michael A O'Rorke; Marie M Cantwell; Christian C Abnet; And John D Brockman; Liam J Murray Journal: Int J Cancer Date: 2012-03-06 Impact factor: 7.396
Authors: Amy L Silvers; Lin Lin; Adam J Bass; Guoan Chen; Zhuwen Wang; Dafydd G Thomas; Jules Lin; Thomas J Giordano; Mark B Orringer; David G Beer; Andrew C Chang Journal: Clin Cancer Res Date: 2010-03-23 Impact factor: 12.531
Authors: Yumie Takata; Alan R Kristal; Irena B King; Xiaoling Song; Alan M Diamond; Charles B Foster; Carolyn M Hutter; Li Hsu; David J Duggan; Robert D Langer; Helen Petrovitch; James M Shikany; Thomas L Vaughan; Johanna W Lampe; Ross L Prentice; Ulrike Peters Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-07-15 Impact factor: 4.254
Authors: D M Clements; D A Oleesky; S C Smith; H Wheatley; D A Hullin; T J Havard; D J Bowrey Journal: J Clin Pathol Date: 2005-05 Impact factor: 3.411
Authors: Ai Kubo; Theodore R Levin; Gladys Block; Gregory J Rumore; Charles P Quesenberry; Patricia Buffler; Douglas A Corley Journal: Am J Gastroenterol Date: 2008-07 Impact factor: 10.864
Authors: John P Gerstenberger; Scott R Bauer; Erin L Van Blarigan; Eduardo Sosa; Xiaoling Song; John S Witte; Peter R Carroll; June M Chan Journal: Prostate Date: 2014-10-04 Impact factor: 4.104